Dolastatin 10 vs Didemnin B
Head-to-head comparison of Dolastatin 10 (Dolastatin 10) and Didemnin B (Didemnin B) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Dolastatin 10 | Didemnin B |
|---|---|---|
| Category | Experimental | Experimental |
| Full Name | Dolastatin 10 | Didemnin B |
| Molecular Weight | 771.0 Da | 1112.4 Da |
| Half-Life | N/A | N/A |
| Amino Acids | 5 | N/A |
| Typical Dose | N/A in humans; subnanomolar to low-nanomolar in vitro | 0.05-2 mg/m2 IV in early trials |
| Route | Intravenous | Intravenous |
| Purity | ≥98% | ≥98% |
| Studies Count | 300 | 120 |
| Research Status | Pre-clinical | Clinical |
Dolastatin 10 Benefits
- ✓antineoplastic
- ✓microtubule disruption
- ✓antimitotic
- ✓ADC payload scaffold
Didemnin B Benefits
- ✓antineoplastic
- ✓antiviral
- ✓pro-apoptotic
- ✓immunomodulatory
Dolastatin 10 Dosing
research-grade in vitro nanomolar use|early IV oncology exploration|no approved dosing regimen
Didemnin B Dosing
historic IV phase I/II oncology regimens|dose escalation in early trials|no approved dosing regimen
Dolastatin 10 Side Effects
- ⚠peripheral neuropathy
- ⚠neutropenia
- ⚠fatigue
Didemnin B Side Effects
- ⚠nausea
- ⚠vomiting
- ⚠myelosuppression
Research Overview
Dolastatin 10
Dolastatin 10 became famous for extreme cytotoxic potency and its ability to block tubulin polymerization. Although the native compound itself did not become a standard therapy, it inspired a major class of clinically important auristatin-based payloads.
Didemnin B
Didemnin B showed strong cytotoxic and antiviral activity in early literature and became an important scaffold for later marine drug development. Its clinical progress was limited by toxicity, but it remains highly cited as a foundational marine depsipeptide.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.